MEDICURE REITERATES ITS COMMITMENT TO PROVIDING EXCEPTIONAL ACCESS TO ITS BRANDED PITAVASTATIN (ZYPITAMAG) TO PEOPLE LIVING WITH HIV
August 29, 2023
Our vision is to become a leading pharmaceutical company within the U.S., offering a growing portfolio of products that improve patients' lives.
At Medicure, we are focused on improving the health of patients by offering a growing portfolio of products and services and ensuring all patients get access to care they need.
We announced our quarter ended June 30, 2023 financial results.
Medicure to present financial results for quarter ended June 30, 2023 and upcoming conference call on Monday July 31, 2023
At Medicure, our mission is to serve patients by delivering safe and efficacious life-changing medicines
Medicure Inc.– via Marley Drug, creates a direct-to-consumer e-commerce pharmacy solution. The service is available in all 50 states and can fulfill a formulary of over 100 prescription medications.
Medicure has filed with the FDA an IND for the use of MC-1 as a novel treatment for seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.
At Medicure, we are focused on improving the heart health of patients by delivering safe and efficacious cardiovascular medicines and ensuring all patients get access to therapy.
Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial in Patients with Aneurysmal Subarachnoid Hemorrhage
Leadership
Board of Directors
Our History
Mission and Values
Medicure Marks Its 25th Anniversary
People and Culture
Careers
AGGRASTAT® (tirofiban HCl) injection
Zypitamag®
Sodium Nitroprusside Injection
Pipeline
Drug Safety
Medical Information
Patient Information
Events
Presentations / Conference Calls
Stock Information
Annual Reports
Quarterly Reports
Corporate Governance
Investor Contacts
Copyright © 2023 Medicure Inc. All Rights Reserved. | Privacy Statement